Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LifeMD, Inc.LFMD · Entity 6521 | Chief Acquisition Officer | September 10, 2025 | September 12, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LifeMD, Inc.
Report date September 10, 2025 · Filed September 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 605,000 |
Reported balance
After 2025-09-10 transaction · row 1
1 source rowRow 1 · 2025-09-10 · Sale · Disposed 75,000 · Balance 605,000 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.87 and $5.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the ranges set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.87 and $5.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the ranges set forth above.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2025 Filed Sep 12, 2025 20:32 UTC | LifeMD, Inc. LFMD · Entity 6521 | SaleCommon Shares | 75,000 | $5.92 | $443,760.00 |
DisclosureSEC source: 0000912282-25-000978 · form4.xml · nonDerivative · entry 1 Alvarez Nicholas P · CIK 0001802844 · Chief Acquisition Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 605,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.87 and $5.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the ranges set forth above. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 22:09 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Shares | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000908 · form4.xml · nonDerivative · entry 1 Alvarez Nicholas P · CIK 0001802844 · Chief Acquisition Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 680,000 F1 · price: Represents grant of performance stock which vested on August 22, 2025 Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:59 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Shares | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000367 · form4.xml · nonDerivative · entry 1 Alvarez Nicholas P · CIK 0001802844 · Chief Acquisition Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 580,000 F1 · price: Represents grant of performance stock which vested on March 31, 2025. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 17:03 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001362118-24-000008 · primary_doc.xml · nonDerivative · entry 1 Alvarez Nicholas P · CIK 0001802844 · Chief Acquisition Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 405,000 F1 · price: Performance shares vested on March 21, 2024. Read SEC document |
| March 07, 2024 Filed Mar 11, 2025 22:19 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Shares | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000283 · form4.xml · nonDerivative · entry 1 Alvarez Nicholas P · CIK 0001802844 · Chief Acquisition Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 505,000 F1 · price: Represents grant of performance stock which vested on March 7, 2025. Read SEC document |
| July 12, 2023 Filed Jul 13, 2023 19:11 UTC | LifeMD, Inc. LFMD · Entity 6521 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 200,000 | Not disclosed Strike: $7.92 | Not disclosed |
DisclosureSEC source: 0001362118-23-000048 · primary_doc.xml · derivative · entry 2 Alvarez Nicholas P · CIK 0001802844 · Chief Acquisition Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires not disclosed F1 · price: The options are being cancelled in exchange for 150,000 restricted shares, with 25,000 vesting on July 12, 2023, 50,000 vesting on January 1, 2024 and 75,000 vesting on January 1, 2025, and performance shares to be reported on settlement. The options vested and became exercisable in equal monthly tranches, based on the passage of time, over the 36 months following December 8, 2020. F1 · derivative.exercise_date: The options are being cancelled in exchange for 150,000 restricted shares, with 25,000 vesting on July 12, 2023, 50,000 vesting on January 1, 2024 and 75,000 vesting on January 1, 2025, and performance shares to be reported on settlement. The options vested and became exercisable in equal monthly tranches, based on the passage of time, over the 36 months following December 8, 2020. F1 · derivative.expiration_date: The options are being cancelled in exchange for 150,000 restricted shares, with 25,000 vesting on July 12, 2023, 50,000 vesting on January 1, 2024 and 75,000 vesting on January 1, 2025, and performance shares to be reported on settlement. The options vested and became exercisable in equal monthly tranches, based on the passage of time, over the 36 months following December 8, 2020. Read SEC document |
| July 12, 2023 Filed Jul 13, 2023 19:11 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Stock | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001362118-23-000048 · primary_doc.xml · nonDerivative · entry 1 Alvarez Nicholas P · CIK 0001802844 · Chief Acquisition Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,000 F1 · price: The options are being cancelled in exchange for 150,000 restricted shares, with 25,000 vesting on July 12, 2023, 50,000 vesting on January 1, 2024 and 75,000 vesting on January 1, 2025, and performance shares to be reported on settlement. The options vested and became exercisable in equal monthly tranches, based on the passage of time, over the 36 months following December 8, 2020. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 14:16 UTC | LifeMD, Inc. LFMD · Entity 6521 | PurchaseCommon Stock | 10,712 | $2.92 | $31,279.04 |
DisclosureSEC source: 0001362118-23-000039 · primary_doc.xml · nonDerivative · entry 1 Alvarez Nicholas P · CIK 0001802844 · Chief Acquisition Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Read SEC document |
| February 11, 2022 Filed Mar 4, 2022 17:30 UTC | LifeMD, Inc. LFMD · Entity 6521 | GiftCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001362118-22-000020 · primary_doc.xml · nonDerivative · entry 1 Alvarez Nicholas P · CIK 0001802844 · Chief Acquisition Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,288 Read SEC document |
| December 08, 2020 Filed Dec 11, 2020 22:15 UTC | LifeMD, Inc. CVLB · Entity 6521 | GrantOptions to purchase Common Stock · Derivative | 200,000 | $0.00 Strike: $7.92 | $0.00 |
DisclosureSEC source: 0001493152-20-023414 · ownership.xml · derivative · entry 1 Alvarez Nicholas P · CIK 0001802844 · Chief Acquisition Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock, par value $0.001 · 200,000 shares Expires not disclosed F1 · shares: The Options were issued to Mr. Alvarez pursuant to the terms of an amended and restated employment agreement, dated December 8, 2020 (the "Effective Date"), by and between Mr. Alvarez and the Issuer. The options shall vest at a rate of 5,555 options each month for thirty-five (35) consecutive months beginning on the Effective Date, with the final 5,575 shares vesting on December 8, 2023. F1 · price: The Options were issued to Mr. Alvarez pursuant to the terms of an amended and restated employment agreement, dated December 8, 2020 (the "Effective Date"), by and between Mr. Alvarez and the Issuer. The options shall vest at a rate of 5,555 options each month for thirty-five (35) consecutive months beginning on the Effective Date, with the final 5,575 shares vesting on December 8, 2023. F1 · derivative.exercise_date: The Options were issued to Mr. Alvarez pursuant to the terms of an amended and restated employment agreement, dated December 8, 2020 (the "Effective Date"), by and between Mr. Alvarez and the Issuer. The options shall vest at a rate of 5,555 options each month for thirty-five (35) consecutive months beginning on the Effective Date, with the final 5,575 shares vesting on December 8, 2023. F1 · derivative.expiration_date: The Options were issued to Mr. Alvarez pursuant to the terms of an amended and restated employment agreement, dated December 8, 2020 (the "Effective Date"), by and between Mr. Alvarez and the Issuer. The options shall vest at a rate of 5,555 options each month for thirty-five (35) consecutive months beginning on the Effective Date, with the final 5,575 shares vesting on December 8, 2023. Read SEC document |
| November 27, 2020 Filed Dec 1, 2020 22:23 UTC | LifeMD, Inc. CVLB · Entity 6521 | Exercise / conversionOptions to purchase Common Stock · Derivative | 105,288 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001493152-20-022775 · ownership.xml · derivative · entry 2 Alvarez Nicholas P · CIK 0001802844 · Chief Acquisition Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 105,288 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents a cashless exercise of outstanding stock options to purchase 120,000 shares of common stock. Mr. Alvarez received 105,288 shares of common stock and surrendered 14,712 shares of common stock underlying the option in payment of the exercise price. The Options were issued to Mr. Alvarez pursuant to the terms of an employment agreement, dated July 26, 2018, by and between Mr. Alvarez and the Issuer. F1 · derivative.exercise_date: Represents a cashless exercise of outstanding stock options to purchase 120,000 shares of common stock. Mr. Alvarez received 105,288 shares of common stock and surrendered 14,712 shares of common stock underlying the option in payment of the exercise price. The Options were issued to Mr. Alvarez pursuant to the terms of an employment agreement, dated July 26, 2018, by and between Mr. Alvarez and the Issuer. F1 · derivative.expiration_date: Represents a cashless exercise of outstanding stock options to purchase 120,000 shares of common stock. Mr. Alvarez received 105,288 shares of common stock and surrendered 14,712 shares of common stock underlying the option in payment of the exercise price. The Options were issued to Mr. Alvarez pursuant to the terms of an employment agreement, dated July 26, 2018, by and between Mr. Alvarez and the Issuer. Read SEC document |
| November 27, 2020 Filed Dec 1, 2020 22:23 UTC | LifeMD, Inc. CVLB · Entity 6521 | Exercise / conversionCommon Stock, par value $0.001 | 105,288 | $1.15 | $121,081.20 |
DisclosureSEC source: 0001493152-20-022775 · ownership.xml · nonDerivative · entry 1 Alvarez Nicholas P · CIK 0001802844 · Chief Acquisition Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents a cashless exercise of outstanding stock options to purchase 120,000 shares of common stock. Mr. Alvarez received 105,288 shares of common stock and surrendered 14,712 shares of common stock underlying the option in payment of the exercise price. The Options were issued to Mr. Alvarez pursuant to the terms of an employment agreement, dated July 26, 2018, by and between Mr. Alvarez and the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.